Evoca S.P.A.
USPTO PatentsView assignee record - 14 granted patents across 16 technology areas, recorded in grant years 2019–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: G07F (Coin-freed OR Like Apparatus).
The verdict
According to USPTO PatentsView, Evoca ranks #19,742 of 49,997 tracked US assignees by granted-patent volume, with 14 patents across 16 technology areas.
- #19,742
- of 49,997 US assignees by volume
- Top 35%
- by Innovation Score (40.5/100)
- 10.6
- avg claims per patent
- +450%
- grant velocity, last 5 yrs
USPTO PatentsView assignee plate
Corpus R19742 · Foreign Corporation #19,742 · 14 grants
GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-FOCUS · INNOV-PAR · CLAIMS-PAR · TYPE-FRNCORP · VEL-SURGE · BOOK-FULL
- GRANTS-MICRO 14 grants
- MID-PACK #19,742/49,997
- PHOTO-FINISH Essentialis
- CPC-FOCUS G07F · 16 areas
- INNOV-PAR 40.5/100
- CLAIMS-PAR 10.6 claims/avg
- TYPE-FRNCORP Foreign Corp
- VEL-SURGE +450% vel
- BOOK-FULL 10/10 fields
Nearest grant-volume peer: Essentialis, Inc. (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
How Evoca’s 40.5 Innovation Score adds up
The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.
Innovation-score neighbourhood around Evoca
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
- Qualcomm Incorporated · highest
Qualcomm Incorporated · highest
85 score
- Evoca S P A · this assignee
Evoca S P A · this assignee
41 score
- 3D Lighting… · lowest 7
3D Lighting… · lowest
7 score
What this shows Evoca's Innovation Score is 40.5/100 (top 35% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.
Does more volume mean deeper claims for Evoca?
Each dot is one of Evoca’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Evoca’s own 10.6 claims/patent is at or below the 17.2 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.
Where Evoca's grants concentrate
Evoca S.P.A. is a focused PatentsView assignee: 16 CPC subclasses with 64.3% of grants classified under G07F (Coin-freed OR Like Apparatus). Peak complete grant year is 2024 (4 grants) versus a trough of 1 in 2020. By volume, Evoca sits between Essentialis, Inc. and Eximo Medical Ltd..
Evoca's three-year grant acceleration
Evoca S.P.A. shows 8 grants in 2022–2024 against only 5 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.
Who files at Evoca's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Essentialis
Essentialis, Inc.
14 patents
- Essex Laboratories
Essex Laboratories, LLC
14 patents
- Etablissements Ge…
Etablissements Georges Renault
14 patents
- Everysight
Everysight Ltd.
14 patents
- Evolution Well Se…
Evolution Well Services, LLC
14 patents
- Exablox
Exablox Corporation
14 patents
- Exail
EXAIL
14 patents
- Eximo Medical
Eximo Medical Ltd.
14 patents
- Evoca S P A ◀
Evoca S.P.A.
14 patents
What this shows Evoca holds 14 patents at rank #19,722, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Evoca
By rank, the assignees closest to #19,722 in granted patent volume.
- Essentialis, Inc. #19,718 · 14 patents
- Essex Laboratories, LLC #19,719 · 14 patents
- Etablissements Georges Renault #19,720 · 14 patents
- Everysight Ltd. #19,721 · 14 patents
- Evolution Well Services, LLC #19,723 · 14 patents
- Exablox Corporation #19,724 · 14 patents
- EXAIL #19,725 · 14 patents
- Eximo Medical Ltd. #19,726 · 14 patents
Leaders in G07F (Coin-freed OR Like Apparatus)
Other assignees with the most granted patents in Evoca's primary technology class.
Evoca's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
41 Top 35% higher than 65% of 49,997 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2019–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2019 | 2 | 14.3% |
| 2020 | 1 | 7.1% |
| 2021 | 2 | 14.3% |
| 2022 | 2 | 14.3% |
| 2023 | 2 | 14.3% |
| 2024 | 4 | 28.6% |
| 2025partial year | 1 | 7.1% |
Which technologies does Evoca S.P.A. patent most?
Top 15 of 16 technology areas
Data Source
USPTO PatentsView, US granted patents 2015–2025
What to do with this data
Evoca S.P.A.'s patent record in context - here's where to go next.
- Evoca S.P.A.'s lead technology class is G07F (Coin-freed OR Like Apparatus), 64.3% of its portfolio - see every assignee active in that class. Explore G07F
- Ranked #19,742 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
- Compare Evoca S.P.A. against Essentialis, Inc., an assignee filing at a similar volume. Compare portfolios
- Innovation Score of 40.5/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated
Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.